Targeted therapy in thyroid cancer: molecular alterations and clinical management - Takeaways - MDSpire

Targeted therapy in thyroid cancer: molecular alterations and clinical management

  • By

  • YiHeng Yang

  • YeSheng Zhang

  • YongCan Xu

  • XiaoXin Gu

  • Neng Lou

  • GuoChao Ye

  • June 5, 2026

  • 0 min

Share

  • 1

    Molecular profiling identifies actionable alterations in thyroid cancer, enabling subtype-specific targeted treatment strategies.

  • 2

    Key genomic drivers like BRAF V600E and RET mutations have transformed the management of advanced thyroid cancer.

  • 3

    BRAF/MEK inhibitors and selective RET/TRK inhibitors are effective for specific thyroid cancer mutations.

  • 4

    VEGFR-targeted multikinase inhibitors remain standard care for radioiodine-refractory differentiated thyroid cancer.

  • 5

    Early genomic profiling is crucial for optimizing treatment selection and expanding precision therapy options.

Original Source(s)

Targeted therapy in thyroid cancer: molecular alterations and clinical management

  • by YiHeng Yang, YeSheng Zhang, YongCan Xu, XiaoXin Gu, Neng Lou, GuoChao Ye

  • June 5, 2026

Related Content

A case report of splenic malignancy originating from the liver

Monomorphic epitheliotropic intestinal T-cell lymphoma presenting as acute small intestinal perforation: a case report and exploratory BCL-2–targeted therapy

Integrating In silico perturbation with multilayer omics to decode regulatory networks in cancer immunity: a new frontier in precision oncology